Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung

Por HUANG, CHU-YUN, CHEN, YUH-MIN, WU, CHIEH-HUNG, TSAI, CHUN-MING, LEE, YU-CHIN, PERNG, REURY-PERNG, WHANG-PENG, JACQUELINE
Publicado em 2014

Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib

Por CHEN, YUH-MIN, FAN, WEN-CHIEN, TSENG, PEI-CHUN, TSAI, CHUN-MING, CHOU, TEH-YING, WU, CHIEH-HUNG, CHOU, KUN-TA, LEE, YU-CHIN, PERNG, REURY-PERNG, WHANG-PENG, JACQUELINE
Publicado em 2011

Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations

Por WU, WEN-SHUO, CHEN, YUH-MIN, TSAI, CHUN-MING, SHIH, JEN-FU, CHIU, CHAO-HUA, CHOU, KUN-TA, LAI, SHINN-LIANG, WU, CHIEH-HUNG, LUO, YUNG-HUNG, HUANG, CHU-YUN, LEE, YU-CHIN, PERNG, REURY-PERNG, WHANG-PENG, JACQUELINE
Publicado em 2012